Human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinomas: role of the gastroenterologist - 21/06/16
Doi : 10.1016/j.gie.2014.12.040
Jason Y. Park, MD, PhD 1, ⁎, Kerry B. Dunbar, MD, PhD 2, 3, Roopa Vemulapalli, MD 3, David H. Wang, MD, PhD 2, 4, Paul J. Zhang, MD 5
1 Department of Pathology, Eugene McDermott Center for Human Growth and Development, Children’s Medical Center, and University of Texas Southwestern Medical Center, Dallas, Texas, USA
2 Medical Service, Dallas Veterans Affairs Medical Center, Dallas, Texas, USA
3 Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
4 Division of Hematology-Oncology, Department of Internal Medicine and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
5 Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
∗Reprint requests: Jason Y. Park, MD, PhD, Department of Pathology, Children’s Medical Center, 1935 Medical District Drive, Dallas, TX 75235.
Abbreviations : 5-FU, FDA, FISH, GEJ, HER2, IHC, ISH, NBF, NCCN, ToGA trial
Plan
| DISCLOSURE: All authors disclosed no financial relationships relevant to this publication. |
© 2015
American Society for Gastrointestinal Endoscopy. Tous droits réservés.
Vol 81 - N° 4
P. 977-982 - avril 2015 Retour au numéro
Article précédent
- Continuing Medical Education Exam: April 2015
- James Buxbaum, Karthik Ravi, William Ross, Brian Weston, Prasad G. Iyer, David Schwartz, Michael B. Wallace
- Endosonography, 3rd Edition
- Todd H. Baron, Ian S. Grimm
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?